Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on July 22, 2025
uniQure to Announce Second Quarter 2025 Financial Results
GlobeNewswire
·
July 22, 2025
LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before …
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
GlobeNewswire
·
July 22, 2025
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to …
ProMIS Neurosciences Announces Private Placement Financing
GlobeNewswire
·
July 22, 2025
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded …
Health Canada Authorizes bioLytical’s iStatis Syphilis Test, Boosting Rapid Response to Rising Infections in Canada
GlobeNewswire
·
July 22, 2025
Now authorized for professional use in Canada, the iStatis Syphilis Antibody Test offers a fast, accurate, and portable solution to strengthen syphilis screening efforts nationwide. Health Canada authorizes the iStatis Syphilis Antibody Test for …
Santé Canada autorise le test de dépistage de la syphilis iStatis de bioLytical, afin de renforcer la réponse rapide à l’augmentation des infections au Canada
GlobeNewswire
·
July 22, 2025
Maintenant autorisé à une utilisation professionnelle au Canada, le test de dépistage des anticorps de la syphilis iStatis offre une solution rapide, précise et portable pour renforcer les efforts de dépistage de la syphilis dans tout le pays. Santé Canada …
Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation
GlobeNewswire
·
July 22, 2025
PRESS RELEASE Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment …
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
GlobeNewswire
·
July 22, 2025
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to …
InspireMD to Announce Second Quarter 2025 Financial Results
GlobeNewswire
·
July 22, 2025
MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, …
Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis
GlobeNewswire
·
July 22, 2025
Financing led by Suvretta Capital Management and SR One with participation from 16 additional healthcare investors Proceeds will support key clinical milestones across all of Avalyn’s pipeline programs CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- …
Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors
GlobeNewswire
·
July 22, 2025
MEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Morphoceuticals Inc., a TechBio company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of industry veteran Roger Pomerantz, MD, as Chairman …
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
GlobeNewswire
·
July 22, 2025
WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
GlobeNewswire
·
July 22, 2025
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July …
OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US
GlobeNewswire
·
July 22, 2025
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the first patient has been dosed in the Phase 2 portion of the Phase 1/2 BIPAVE-001 trial ( …
Seres Therapeutics Announces Leadership Transition
GlobeNewswire
·
July 22, 2025
Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including …
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
GlobeNewswire
·
July 22, 2025
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) …
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
GlobeNewswire
·
July 22, 2025
CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in …
Telix Reports $204M Revenue, Up 63% YOY
GlobeNewswire
·
July 22, 2025
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All …
Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
GlobeNewswire
·
July 22, 2025
CARDIFF, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, today announces the appointments of Bob Yang as Chief Medical Officer (CMO), Maddy Kennedy as Chief Financial Officer (CFO), and Mark …
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights
GlobeNewswire
·
July 22, 2025
San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD …
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
GlobeNewswire
·
July 22, 2025
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, …